Microsomal prediction of in vivo clearance of CYP2C9 substrates in humans

British Journal of Clinical Pharmacology

Volumn 47, Issue 6, 1999, Pages 625-635

  Carlile, David J ^a   Hakooz, Nancy ^a   Bayliss, Martin K ^b   Houston, J Brian ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

CYP2C9; Human microsomes; In vitro predictions; Intrinsic clearance

Indexed keywords

ALBUMIN; CYTOCHROME P450; DICLOFENAC; IBUPROFEN; PHENYTOIN; TOLBUTAMIDE;

ARTICLE; CONTROLLED STUDY; DATA ANALYSIS; DRUG CLEARANCE; DRUG METABOLISM; DRUG PROTEIN BINDING; HUMAN; HUMAN CELL; LIVER MICROSOME; MICHAELIS CONSTANT; PREDICTION; PRIORITY JOURNAL;

ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; METABOLIC CLEARANCE RATE; MICROSOMES, LIVER; PHENYTOIN; STEROID 16-ALPHA-HYDROXYLASE; STEROID HYDROXYLASES; TOLBUTAMIDE;

EID: 0032995197     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1999.00935.x     Document Type: Article

References (53)

1. 1 Houston JB. Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. Biochem Pharmacol 1994; 47: 1469-1479.
2. 2 Houston JB, Carlile DJ. Prediction of hepatic clearance from microsomes, hepatocytes and liver slices. Drug Met Rev 1997; 29: 891-922.
3. 3 Iwatsubo T, Hirota N, Ooic T, et al. Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data. Pharmacol Ther 1997; 73: 147-171.
4. 4 Miners JO, Birkett DJ. Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. Br J Clin Pharmacol 1998; 45: 525-538.
5. 5 Guengerich FP, Turvy CG. Comparison of levels of several human microsomal cytochrome P-450 enzymes and epoxide hydrolase in normal and disease states using immunochemical analysis of surgical liver samples. J Pharmacol Exp Ther 1991; 256: 1189-1195.
6. 6 Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 1994; 270: 414-423.
7. 7 Forrester LM, Henderson CJ, Glancey MJ, et al. Relative expression of cytochrome P450 isoenzymes in human liver and associations with the metabolism of drugs and xenobiotics. Biochem J 1992; 281: 359-368.
8. 8 Veronese ME, Miners JO, Rees DLP, Birkett DJ. Tolbutamide hydroxylation in humans: lack of bimodality in 106 healthy subjects. Pharmacogenenetics 1993; 3: 86-93.
9. 9 Dickinson RG, Hooper WD, Patterson M, Eadie MJ, Maguire B. Extent of urinary excretion of p-hydroxyphenytoin in healthy subjects given phenytoin. Ther Drug Monit 1985; 7: 283-289.
10. 10 Thomas RC, Ikeda GJ. The metabolic fate of tolbutamide in man and in the rat. J Med Chem 1966; 9: 507-510.
11. 11 Rudy AC, Knight PM, Brater DC, Hall SD. Stereoselective metabolism of ibuprofen in humans: administration of R-, S-and racemic ibuprofen. J Pharmacol Exp Ther 1991; 259: 1133-1139.
12. 12 Riess W, Stierten H, Geiger UP, et al. Data on the pharmarokinetics and metabolism of diclofenac (Voltaren) in animals and man. In: Chronic Forms of Polyarthritis, Ed Wagenhauser FJ, Berne, Stuttgart and Vienna: Huber, 1976; 302-317.
13. 13 Stierlin H, Faigle JW, Sallmann A, et al. Biotransformation of diclofenac sodium (Voltaren) in animals and in man I. Isolation and identification of principal metabolites. Xenobiotica 1979; 9: 601-610.
14. m values: Implications for clinical correlation. J Pharmacol Exp Ther 1997; 282: 391-396.
15. 15 Tassanecyakul W, Veronese ME, Birkett DJ, et al. Co-regulation of phenytoin and tolbutamide metabolism in humans. Br J Clin Pharmacol 1992; 34: 494-498.
16. 16 Evans AM, Nation RL, Sansom LN, Bochner F, Somogyi AA. Stereoselectivc plasma protein binding of ibuprofen enantiomers. Eur J Clin Pharmacol 1989; 36: 283-290.
17. 17 John VA. The pharmacokinetics and metabolism of diclofenac sodium (Voltarol) in animals and man. Rheumatol Rehab Suppl 1979; 2: 22-37.
18. 18 Chan KKH, Vyas KH, Brandt KD. In vitro protein binding of diclofenac sodium in plasma and synovial fluid. J Pharm Sci 1987; 76: 105-108.
19. 19 Ashforth EH, Carlile DJ, Chenery R, Houston JB. Prediction of in vivo disposition from in vitro systems: Clearance of phenytoin and tolbutamide using rat hepatic microsomal and hepatocyte data. J Pharmacol Exp Ther 1995; 274: 761-766.
20. 20 Omura T, Sato R. The carbon monoxide binding pigment of liver microsomes. J Biol Chem 1964; 239: 2370-2378.
21. 21 Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the folin phenol reagent. J Biol Chem 1951; 193: 265-275.
22. 22 Lockvvood GF, Wagner JG. High-performance liquid chromatographic determination of ibuprofen and its major metabolites in biological fluids. J Chromatogr 1982; 232: 335-343.
23. 23 Hamman MA, Thompson GA, Hall SD. Regioselective and stereoselective metabolism of ibuprofen by human cytochrome P450, 2C. Biochem Pharmacol 1997 54: 33-41.
24. 24 Godbillon J, Gauron S, Metayer JP. High perfomance liquid chromatographic determination of diclofenac and its monohydroxylated metabolites in biological fluids. J Chromatogr 1985; 338: 151-159.
25. 25 Doecke CJ, Veronese ME, Pond SM, et al. Relationship between phenytoin and tolbutamide hydroxylations in human liver microsomes. Br J Clin Pharmacol 1991; 31: 125-130.
26. 26 Miners JO, Smith KJ, Robson RA, McManus ME, Veronese ME, Birkett DJ. Tolbutamide hydroxylation by human liver microsomes. Kinetic characterisation and relationship to other cytochrome P-450 dependent xenobiotic oxidations. Biochem Pharmacol 1988; 37: 1137-1144.
27. 27 Back DJ, Stevenson P, Tjia JF. Comparative effects of two antimycotic agents, ketoconazole and terbinafine on the metabolism of tolbutamide, ethinyloestradiol, cyclosporin and ethoxycoumarin by human liver microsomes in vitro. Br J Clin Pharmacol 1989; 28: 166-170.
28. 28 Leeman T, Transon C, Dayer P. Cytochrome P 450TB, (CYP2C): a major monooxygenase catalyzing diclofenac 4′hydroxylation in human liver. Life Sci 1992; 52: 29-34.
29. 29 Shen S, Marchick MR, Davis MR, Pohl LR. 5-Hydroxylation of diclofenac by human cytochrome P450 3A4: Possible role in idiosyncratic hepatotoxicity. ISSX Proceedings, 6th European ISSX Meeting, Gothenburg, 1997; 102.
30. 30 Eisenthal R, Cornish-Bowden A. The direct linear plot. A new graphical procedure for estimating enzyme kinetic parameters. Biochem J 1974; 139: 715-720.
31. 31 Rowland M, Tozer N. Blood to plasma concentration ratio. In Clinical Pharmacokinetics Concepts and Applications 2nd edn. eds. Rowland M, Tozer TN, Lea and Febiger, Philadelphia and London, 1989; 476-478.
32. 32 Schmucker DL, Woodhouse KW, Wang RK, et al. Effects of age and gender on in vitro properties of human liver microsomal monooxygenases. Clin Pharmacol Ther 1990; 48: 365-374.
33. 33 Baarnhielm C, Dahlback H, Skanberg I. In vivo pharmacokinetics of felodipine predicted from in vitro studies in rat, dog and man. Acta Pharmacol Toxicol 1986; 59: 113-122.
34. 34 Carlile DJ, Zomorodi K, Houston JB. Scaling factors to relate drug metabolic clearance in hepatic microsomes, isolated hepatocytes and the intact liver. Studies with induced livers involving diazepam. Drug Metab Disp 1997; 25: 903-911.
35. 35 Eadie MJ, Tyrer JH, Bochner F, Hooper WD. The elimination of phenytoin in man. Clin Exp Pharmacol Physiol 1976; 3: 217-224.
36. 36 Jusko WJ. Bioavailability and disposition kinetics of phenytoin in man. In Quantitative Analytic Studies in Epilepsy eds. Kellaway P, Petersen 1, New York: Raven Press, 1976; 115-136.
37. 37 Winter ME, Tozer TN. Phenytoin. In Applied Pharmacokinetics: Principles of Theraputic Drug Monitoring 2nd edn. eds. Evans WE, Schentag JJ, Jusko WJ, Vancouver, WA. Applied Therapeutics Inc. 1986: 493-539.
38. 38 Svendsen TL, Kristensen MB, Hansen JM, Skovsted L. The influence ot disulfiram on the half life and metabolic clearance rate of diphenylhydantoin and tolbutamide in man. Eur Clin Pharmacol 1976; 9: 439-441.
39. 39 Gugler R, Manion CV, Azarnoff DL. Phenytoin: Pharmacokinetics and bioavailability. Clin Pharmacol Ther 1976; 19: 135-142.
40. 40 Grasela TH, Sheiner LB, Rambeck B, et al. Steady-state pharmacokinetics of phenytoin from routinely collected patient data. Clin Pharmacokinet 1983; 8: 355-364.
41. 41 Kurata D, Wilkinson GR. Erythroeyte uptake and plasma binding of diphenylhydantoin. Clin Pharmacol Ther 1974; 16: 355-362.
42. 42 Carulli N, De Ponz Leon M, Mauro E, Manenti F, Ferran A. Alteration of drug metabolism in Gilbert's syndrome. Gut 1976; 17: 581-587.
43. 43 Williams RL, Blaschke TF, Meffin PJ, Mehnon KL, Rowland M. Influence of acute viral hepatitis on disposition and plasma binding of tolbutamide. Clin Pharmacol Ther 1977; 21: 301-309.
44. 44 Zilly W, Breimer DD, Richter E. Stimulation of drug metabolism by rifampicin in patients with cirrhosis or cholestasis measured by increased hexobarbital and tolbutamide clearance. Eur J Clin Pharmacol 1977; 11: 287-293.
45. 45 Wing LMH, Miners JO. Cotrimazole as an inhibitor of oxidative drug metabolism; effects of trimethoprim and sulphamethoxazole separately and combined on tolbutamide disposition. Br J Clin Pharmacol 1985; 20: 482-485.
46. 46 Back DJ, Tjia J, Monig H, Ohnhans EE, Park BK. Selective inhibition of drug oxidation after simultaneous administration of two probe drags, antipyrine and tolbutamide. Eur J Clin Pharmacol 1988; 34: 157-163.
47. 47 Veronese ME, Miners JO, Randles GD, Birkett DJ. Validation of the tolbutamide metabolic ratio for population screening with use of sulphaphenazole to produce model phenotypic metabolizers. Clin Pharmacol Ther 1990; 47: 403-411.
48. 48 Page MA, Boutagy JS, Shenfield GM. A screening test for slow metabolisers of tolbutamide. Br J Clin Pharmacol 1991; 31: 649-654.
49. 49 Lee EJD, Williams K, Day R, Graham G, Champion D. Stereoselective disposition of ibuprofen enantiomers in man. Br J Clin Pharmacol 1985; 19: 669-674.
50. 50 Willis JV, Kendall MJ, Flinn RM, Thornhill DP, Welling PG. The pharmacokinetics of diclofenac sodium following intravenous and oral adminstration. Eur J Clin Pharmacol 1976; 16: 405-410.
51. 51 Drenska A, Ognyanova V, Tomoy I, et al. Feloran (diclofenac sodium). Pharmacokinetics in experimental animals and humans after oral administration. Med Biol Inform 1984; 2: 12-16.
52. 52 Degen PH, Dieterle W, Schneider W, Theobald W, Sinterhauf U. Pharmacokinetics of diclofenac and five metabolites after single doses in healthy volunteers and after repeated doses in patients. Xenobiotica 1988; 18: 1449-1455.
53. TB, (CYP2C9) by (±) fluvastatin. Clin Pharmacol Ther 1995; 58: 412-417.